The Cooper Companies, Inc. $COO Stock Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 506.0% in the third quarter, Holdings Channel.com reports. The fund owned 23,166 shares of the medical device company’s stock after purchasing an additional 19,343 shares during the period. International Assets Investment Management LLC’s holdings in Cooper Companies were worth $1,310,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Avalon Trust Co bought a new stake in Cooper Companies in the second quarter valued at $25,000. Elevation Wealth Partners LLC increased its position in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares during the period. Continuum Advisory LLC bought a new position in Cooper Companies in the 2nd quarter worth $30,000. J.Safra Asset Management Corp bought a new position in Cooper Companies in the 2nd quarter worth $32,000. Finally, Sound Income Strategies LLC bought a new position in Cooper Companies in the 1st quarter worth $52,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Paul A. Keel bought 4,701 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was acquired at an average price of $53.18 per share, with a total value of $249,999.18. Following the completion of the purchase, the director owned 4,701 shares of the company’s stock, valued at approximately $249,999.18. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence Kurzius bought 10,000 shares of the stock in a transaction dated Monday, September 14th. The shares were acquired at an average price of $53.91 per share, with a total value of $539,100.00. Following the completion of the acquisition, the director directly owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. The trade was a 90.10% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 34,701 shares of company stock valued at $1,880,039 in the last three months. Company insiders own 2.08% of the company’s stock.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $60.83 on Wednesday. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $11.57 billion, a P/E ratio of 20.76, a P/E/G ratio of 2.41 and a beta of 0.83. The business has a fifty day simple moving average of $59.73 and a two-hundred day simple moving average of $68.89. The Cooper Companies, Inc. has a 12 month low of $51.01 and a 12 month high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company’s revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, equities analysts forecast that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its board has authorized a share buyback plan on Wednesday, September 9th that authorizes the company to repurchase $3 billion in outstanding shares. This buyback authorization authorizes the medical device company to buy up to 22.7% of its stock through open market purchases. Share buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on COO shares. Stifel Nicolaus set a $70.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a research note on Thursday, September 10th. Piper Sandler reissued a “neutral” rating on shares of Cooper Companies in a research note on Thursday, October 15th. Bank of America lowered shares of Cooper Companies from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $80.00 to $65.00 in a report on Thursday, September 10th. Needham & Company LLC cut their price objective on Cooper Companies from $86.00 to $73.00 and set a “buy” rating on the stock in a research report on Thursday, September 10th. Finally, Zacks Research cut Cooper Companies from a “hold” rating to a “strong sell” rating in a research report on Friday, September 11th. Four research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $68.60.

About Cooper Companies

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.